• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

替诺福韦抑制人女性上生殖道和下生殖道上皮细胞和成纤维细胞的愈合。

Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract.

机构信息

Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, One Medical Center Drive, Lebanon, NH, 03756 USA.

出版信息

Sci Rep. 2017 Apr 3;8:45725. doi: 10.1038/srep45725.

DOI:10.1038/srep45725
PMID:28368028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5377941/
Abstract

Disruption of the epithelium in the female reproductive tract (FRT) is hypothesized to increase HIV infection risk by interfering with barrier protection and facilitating HIV-target cell recruitment. Here we determined whether Tenofovir (TFV), used vaginally in HIV prevention trials, and Tenofovir alafenamide (TAF), an improved prodrug of TFV, interfere with wound healing in the human FRT. TFV treatment of primary epithelial cells and fibroblasts from the endometrium (EM), endocervix (CX) and ectocervix (ECX) significantly delayed wound closure. Reestablishment of tight junctions was compromised in EM and CX epithelial cells even after wound closure occurred. In contrast, TAF had no inhibitory effect on wound closure or tight junction formation following injury. TAF accumulated inside genital epithelial cells as TFV-DP, the active drug form. At elevated levels of TAF treatment to match TFV intracellular TFV-DP concentrations, both equally impaired barrier function, while wound closure was more sensitive to TFV. Furthermore, TFV but not TAF increased elafin and MIP3a secretion following injury, molecules known to be chemotactic for HIV-target cells. Our results highlight the need of evaluating antiretroviral effects on genital wound healing in future clinical trials. A possible link between delayed wound healing and increased risk of HIV acquisition deserves further investigation.

摘要

女性生殖道(FRT)上皮细胞的破坏被认为会增加 HIV 感染的风险,因为它会干扰屏障保护并促进 HIV 靶细胞的募集。在这里,我们确定了在 HIV 预防试验中阴道使用的替诺福韦(TFV)和替诺福韦丙酚酯(TAF),一种 TFV 的改良前药,是否会干扰人 FRT 的伤口愈合。TFV 处理子宫内膜(EM)、宫颈内口(CX)和宫颈外口(ECX)的原代上皮细胞和成纤维细胞,显著延迟了伤口闭合。即使在伤口闭合后,EM 和 CX 上皮细胞中的紧密连接的重建也受到了损害。相比之下,TAF 对损伤后的伤口闭合或紧密连接形成没有抑制作用。TAF 在生殖道上皮细胞内积累为 TFV-DP,即活性药物形式。在升高的 TAF 治疗水平以匹配 TFV 细胞内 TFV-DP 浓度时,两者同样损害了屏障功能,而伤口闭合对 TFV 更敏感。此外,TFV 而非 TAF 增加了损伤后 Elafin 和 MIP3a 的分泌,这些分子已知对 HIV 靶细胞具有趋化作用。我们的结果强调了在未来的临床试验中评估抗逆转录病毒对生殖道伤口愈合的影响的必要性。延迟的伤口愈合与 HIV 感染风险增加之间的可能联系值得进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15cc/5377941/ebb3c867929a/srep45725-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15cc/5377941/4c501ef00683/srep45725-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15cc/5377941/57df1fc76aec/srep45725-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15cc/5377941/826e4bfff552/srep45725-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15cc/5377941/e5a16c97a498/srep45725-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15cc/5377941/ebb3c867929a/srep45725-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15cc/5377941/4c501ef00683/srep45725-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15cc/5377941/57df1fc76aec/srep45725-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15cc/5377941/826e4bfff552/srep45725-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15cc/5377941/e5a16c97a498/srep45725-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15cc/5377941/ebb3c867929a/srep45725-f6.jpg

相似文献

1
Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract.替诺福韦抑制人女性上生殖道和下生殖道上皮细胞和成纤维细胞的愈合。
Sci Rep. 2017 Apr 3;8:45725. doi: 10.1038/srep45725.
2
Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells.人女性生殖道的上皮细胞和成纤维细胞积累并释放 TFV 和 TAF,以维持对 CD4+ T 细胞中 HIV 感染的抑制作用。
Sci Rep. 2019 Feb 12;9(1):1864. doi: 10.1038/s41598-018-38205-y.
3
Effects of tenofovir on cytokines and nucleotidases in HIV-1 target cells and the mucosal tissue environment in the female reproductive tract.替诺福韦对HIV-1靶细胞及女性生殖道黏膜组织环境中细胞因子和核苷酸酶的影响。
Antimicrob Agents Chemother. 2014 Nov;58(11):6444-53. doi: 10.1128/AAC.03270-14. Epub 2014 Aug 18.
4
Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.激素避孕药对 TFV 和 TAF 抑制 HIV 感染和 TFV-DP 在血液和生殖道 CD4+T 细胞中的抑制作用存在差异。
Sci Rep. 2017 Dec 18;7(1):17697. doi: 10.1038/s41598-017-18078-3.
5
Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture.性激素在体外培养的女性生殖道细胞中调节二磷酸替诺福韦。
PLoS One. 2014 Jun 30;9(6):e100863. doi: 10.1371/journal.pone.0100863. eCollection 2014.
6
High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.与富马酸替诺福韦二吡呋酯相比,替诺福韦艾拉酚胺的高耐药屏障是由更多的二磷酸替诺福韦进入靶细胞所驱动的。
Antiviral Res. 2016 Aug;132:50-8. doi: 10.1016/j.antiviral.2016.05.012. Epub 2016 May 18.
7
Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.在细胞内浓度超过临床相关药物暴露水平时,替诺福韦艾拉酚胺(TAF)不会消耗人T细胞系中的线粒体DNA。
Antiviral Res. 2017 Apr;140:116-120. doi: 10.1016/j.antiviral.2017.01.014. Epub 2017 Jan 26.
8
Estradiol regulation of nucleotidases in female reproductive tract epithelial cells and fibroblasts.雌激素对女性生殖道上皮细胞和成纤维细胞核苷酸酶的调节作用。
PLoS One. 2013 Jul 25;8(7):e69854. doi: 10.1371/journal.pone.0069854. Print 2013.
9
Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC-MS/MS method.采用灵敏的 LC-MS/MS 方法同时测定乙型肝炎感染肝细胞中的替诺福韦艾拉酚胺及其活性代谢物替诺福韦和替诺福韦二磷酸。
J Pharm Biomed Anal. 2017 Nov 30;146:147-153. doi: 10.1016/j.jpba.2017.08.028. Epub 2017 Aug 30.
10
The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.孕激素储存制剂醋酸甲羟孕酮对食蟹猴中替诺福韦艾拉酚胺的影响。
Antiviral Res. 2021 Feb;186:105001. doi: 10.1016/j.antiviral.2020.105001. Epub 2020 Dec 29.

引用本文的文献

1
Crosstalk between the Resident Microbiota and the Immune Cells Regulates Female Genital Tract Health.常驻微生物群与免疫细胞之间的相互作用调节女性生殖道健康。
Life (Basel). 2023 Jul 9;13(7):1531. doi: 10.3390/life13071531.
2
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.促进女性参与科学和科学服务于女性:填补差距、应对挑战、把握机遇,以优化 HIV-1 预防的暴露前预防措施。
Front Immunol. 2022 Dec 6;13:1055042. doi: 10.3389/fimmu.2022.1055042. eCollection 2022.
3
Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.

本文引用的文献

1
Dendritic cells from the human female reproductive tract rapidly capture and respond to HIV.来自人类女性生殖道的树突状细胞能迅速捕获并对HIV作出反应。
Mucosal Immunol. 2017 Mar;10(2):531-544. doi: 10.1038/mi.2016.72. Epub 2016 Aug 31.
2
Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection.口服恩曲他滨和替诺福韦艾拉酚胺联合化学预防可保护猕猴免受直肠猿猴/人类免疫缺陷病毒感染。
J Infect Dis. 2016 Oct 1;214(7):1058-62. doi: 10.1093/infdis/jiw312. Epub 2016 Jul 27.
3
Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression.
一项随机、安慰剂对照的 I 期临床试验,评估了连续或周期性使用 90 天替诺福韦加左炔诺孕酮阴道环的安全性、药代动力学、药效学和可接受性:CONRAD 138 研究。
PLoS One. 2022 Oct 10;17(10):e0275794. doi: 10.1371/journal.pone.0275794. eCollection 2022.
4
Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.一种可生物降解的植入物释放替诺福韦艾拉酚胺用于阴道保护的安全性和有效性:猕猴模型研究。
J Antimicrob Chemother. 2022 Oct 28;77(11):2964-2971. doi: 10.1093/jac/dkac252.
5
Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue.替诺福韦和替诺福韦艾拉酚胺用于包皮组织中HIV-1暴露前预防的临床前评估
Pharmaceutics. 2022 Jun 16;14(6):1285. doi: 10.3390/pharmaceutics14061285.
6
The Interplay Between Cervicovaginal Microbial Dysbiosis and Cervicovaginal Immunity.宫颈阴道微生物失调与宫颈阴道免疫的相互作用。
Front Immunol. 2022 Mar 10;13:857299. doi: 10.3389/fimmu.2022.857299. eCollection 2022.
7
Medroxyprogesterone acetate inhibits wound closure of human endometrial epithelial cells and stromal fibroblasts in vitro.醋酸甲羟孕酮抑制体外人子宫内膜上皮细胞和基质成纤维细胞的伤口闭合。
Sci Rep. 2021 Dec 1;11(1):23246. doi: 10.1038/s41598-021-02681-6.
8
Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.将替诺福韦转化为具有长效药代动力学特征的稳定 ProTide 纳米晶体。
Nat Commun. 2021 Sep 16;12(1):5458. doi: 10.1038/s41467-021-25690-5.
9
HIV Pathogenesis in the Human Female Reproductive Tract.人类女性生殖道中的 HIV 发病机制。
Curr HIV/AIDS Rep. 2021 Apr;18(2):139-156. doi: 10.1007/s11904-021-00546-1. Epub 2021 Mar 15.
10
Impact of Q-Griffithsin anti-HIV microbicide gel in non-human primates: In situ analyses of epithelial and immune cell markers in rectal mucosa.Q-格里菲辛抗 HIV 杀微生物剂凝胶对非人类灵长类动物的影响:直肠黏膜上皮细胞和免疫细胞标志物的原位分析。
Sci Rep. 2019 Dec 2;9(1):18120. doi: 10.1038/s41598-019-54493-4.
直肠使用1%替诺福韦凝胶与表皮蛋白表达改变有关。
AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):1005-1015. doi: 10.1089/AID.2015.0381. Epub 2016 Aug 2.
4
Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study.HIV血清学不一致关系中的非洲女性亲密伴侣暴力与艾滋病病毒暴露前预防(PrEP)依从性:一项前瞻性队列研究
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):313-322. doi: 10.1097/QAI.0000000000001093.
5
High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.与富马酸替诺福韦二吡呋酯相比,替诺福韦艾拉酚胺的高耐药屏障是由更多的二磷酸替诺福韦进入靶细胞所驱动的。
Antiviral Res. 2016 Aug;132:50-8. doi: 10.1016/j.antiviral.2016.05.012. Epub 2016 May 18.
6
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).替诺福韦艾拉酚胺(TAF)作为富马酸替诺福韦二吡呋酯(TDF)的后续药物。
Biochem Pharmacol. 2016 Nov 1;119:1-7. doi: 10.1016/j.bcp.2016.04.015. Epub 2016 Apr 29.
7
Tenofovir alafenamide for HIV: time to switch?用于治疗艾滋病毒的替诺福韦艾拉酚胺:是时候换药了吗?
Lancet Infect Dis. 2016 Jan;16(1):3-5. doi: 10.1016/S1473-3099(15)00412-0. Epub 2015 Nov 2.
8
Exploring Genitoanal Injury and HIV Risk Among Women: Menstrual Phase, Hormonal Birth Control, and Injury Frequency and Prevalence.探索女性的生殖器官-肛门损伤与艾滋病毒风险:月经周期、激素避孕以及损伤频率和患病率
J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):207-12. doi: 10.1097/QAI.0000000000000824.
9
The Role of Sexual Health Professionals in Developing a Shared Concept of Risky Sexual Behavior as it Relates to HIV Transmission.性健康专业人员在制定与 HIV 传播相关的危险性行为共同概念方面的作用。
Public Health Nurs. 2016 Mar-Apr;33(2):139-50. doi: 10.1111/phn.12216. Epub 2015 Jul 16.
10
Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.在CAPRISA 004试验中,生殖器替诺福韦浓度与预防HIV感染相关:坚持用药对杀微生物剂有效性的重要性。
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):264-9. doi: 10.1097/QAI.0000000000000607.